Company Focus
Gilead Sciences
Latest Gilead Sciences News
Biotechnology
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology. 5 August 2026
Related News
Insights
Company Spotlight
A Minneapolis-based oncology biotech that secured its first FDA approval in July 2026 with Revtorpyk (gedatolisib), the only pan-PI3K and dual mTOR complex inhibitor cleared by the agency, targeting HR+/HER2- metastatic breast cancer.
Latest News & Features of interest to Gilead Sciences
Biotechnology
US clinical-stage biotechnology company Expedition Therapeutics, which is developing novel oral small molecule therapies for inflammatory and respiratory diseases, today announced the closing of an oversubscribed $115 million Series B financing. 5 August 2026
Pharmaceutical
Russia is considering increasing drug procurements against hepatitis C. According to official data, governmental procurements of such drugs over the last year and a half has reached almost 50 billion roubles ($619.2 million), reports The Pharma Letter’s local correspondent. 5 August 2026
Biotechnology
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity (romosozumab) and several newer medicines outweighed declining sales of products facing pricing or biosimilar pressure. 5 August 2026
Biotechnology
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology. 5 August 2026
Biotechnology
Canada-based biotech Defence Therapeutics has announced a significant leadership change, appointing Dr Amie Phinney as president and chief executive (CEO), effective August 1, 2026. 4 August 2026
Biotechnology
Pathos AI, a US clinical-stage AI and technology company advancing its own pipeline of cancer therapies, announced a collaboration and co-exclusive licensing agreement with UK pharma major AstraZeneca. 4 August 2026
Pharmaceutical
US pharma major Pfizer raised the lower end of its full-year revenue forecast after second-quarter sales and adjusted earnings exceeded analyst expectations, with growth across its non-COVID portfolio offsetting sharp declines for Paxlovid (ritonavir) and Comirnaty. 4 August 2026
Pharmaceutical
German pharma and crop science major Bayer posted second-quarter 2026 sales of 10.87 billion euros ($12.39 billion), up 1.2% as reported and 2.2% on a currency- and portfolio-adjusted basis. Core earnings per share fell 16.7% to 0.95 euros ($1.08), held back by a normalization in tax expense and weaker earnings in the group's reconciliation line. 4 August 2026
Pharmaceutical
US pharma major Merck & Co, known as MSD outside the USA and Canada, reported second-quarter sales of $16.61 billion, up 5% year on year and 4% excluding currency, but a one-time charge tied to its Terns Pharmaceuticals takeover pushed the company to a loss on both reported and adjusted measures. 4 August 2026
Biotechnology
Swiss-domiciled oncology company BeOne Medicines has been awarded an Innovation Passport by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for BGB-B2033, an experimental bispecific antibody for hepatocellular carcinoma, the most common form of primary liver cancer. 4 August 2026
Latest In Brief for Gilead Sciences
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze